Cart (0 Items)
Your cart is currently empty.
View Products-
-
-
Concizumab Biosimilar – Anti-TFPI mAb – Research Grade
| Size | 100ug, 1MG |
|---|---|
| Isotype | IgG4, kappa |
| Brand | ProteoGenix |
| Product type | Primary Antibodies |
| Clonality | Monoclonal Antibody |
| Expression system | Mammalian cells |
| Applications | Elisa, WB |
| Product name | Concizumab Biosimilar - Anti-TFPI mAb - Research Grade |
|---|---|
| Source | CAS 1312299-39-0 |
| Species | Humanized |
| Expression system | Mammalian cells |
| Purity | >85% |
| Buffer | PBS buffer PH7.5 |
| Delivery condition | Blue ice (+4°C) |
| Delivery Time | 3-5 days if in stock; 3-5 weeks if production needed |
| Storage condition | store at -80°C |
| Brand | ProteoGenix |
| Aliases /Synonyms | Concizumab,Anti-TFPI,NN7415,mab2021,TFPI,anti-TFPI |
| Reference | PX-TA1306 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype | IgG4-kappa |
| Clonality | Monoclonal Antibody |
Description of Concizumab Biosimilar - Anti-TFPI mAb - Research Grade
General information on Anti-TFPI[Homo sapiens] (Concizumab) Monoclonal Antibody
Concizumab has been investigated for the treatment of Haemophilia A and Congenital Bleeding Disorder.
Related products
Antigen
TFPI, N-His, recombinant protein
PX-P5950 329€
ELISA
Concizumab ELISA Kit
KPTX171 1179€Contact us
Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.
Reviews
There are no reviews yet.